Figure 2: Adjusted mean (95% CI) change from baseline in HbA1c at w24: subgroup analysis. Subgroup analyses were performed to assess the consistency of treatment effects on change from baseline in HbA1c. Patients were stratified by race (white, Asian, black, other) sex, age (<65 or ≥ 65 years), and baseline HbA1c (<8%, 8%–<9%, or ≥9%). Only a few patients identified as “other” in the subgroup for race (saxagliptin 2.5 mg, n=3; saxagliptin 5 mg, n=4; placebo, n=7). The adjusted mean change (95% CI) from baseline in HbA1c in these patients was −1.96 (−3.06, −0.86) in the saxagliptin 2.5 mg group, −1.78 (−2.74, −0.82) in the saxagliptin 5 mg group, and −0.06 (−0.80, 0.68) in the placebo group at week 24. No significant treatment interaction was observed, with the exception of baseline HbA1c (P=0.003). HbA1c=glycated hemoglobin. *Number of randomized patients with baseline and week 24 values.